CRISPR Therapeutics AG (CRSP) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Zug, スイス. 現CEOは Samarth Kulkarni.
CRSP を有する IPO日 2016-10-19, 393 名の正社員, に上場 NASDAQ Global Market, 時価総額 $5.46B.
CRISPR Therapeutics AG is a gene editing company headquartered in Zug, Switzerland, that develops gene-based medicines using its proprietary CRISPR/Cas9 technology platform, which enables precise modifications to genomic DNA. The company's clinical pipeline spans multiple therapeutic areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases, with lead programs such as CTX001 for beta-thalassemia and sickle cell disease, CTX110 and CTX120 for various cancers, and VCTX210 for type 1 diabetes. CRISPR also pursues in vivo gene-editing programs targeting liver, lung, muscle, and central nervous system diseases. The company has established strategic partnerships with major pharmaceutical and biotechnology firms including Bayer, Vertex Pharmaceuticals, ViaCyte, Nkarta, and Capsida Biotherapeutics to advance its therapeutic development efforts.
